Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events?
Cornelis Kluft
Correspondence TNO Gaubius Laboratory, Biomedical Research, Zernikedreef 9, PO Box 2215, Leiden, 2333 CK, The Netherlands
Email C.Kluft@pg.tno.nl
This article has no abstract so we have provided the first paragraph of the full text.
Statin therapy lowers the risk of cardiovascular events by reducing plasma cholesterol levels. Statins also lower the levels of the inflammatory biomarker CRP. In this study, Ridker et al. show that patients receiving statin treatment who have CRP levels of more than 2 mg/l during treatment are at a relatively higher risk of future cardiovascular events than those with CRP levels of less than 2 mg/l, an effect seen regardless of the level of LDL cholesterol achieved. This indicates that the CRP level achieved during treatment remains related to risk and that the 'lower the better' maxim that is applied to cholesterol levels could also be relevant for CRP levels.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Chemical knockout of C-reactive protein in cardiovascular diseaseNature Chemical Biology News and Views (01 Jun 2006)
